mTOR
9 drugs Oncology
7
approved indications
9
Approved Drugs
6
Companies
13
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (6 companies)
✓ All 9 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (13 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Novartis 3 drugs
PF PRISM CV 2 drugs
ALKEM LABS LTD 1 drug
By Therapeutic Area
Other 5 drugs
Oncology 4 drugs
Drugs by Company PRO
Novartis 3 drugs
ALKEM LABS LTD 1 drug
NOBELPHARMA 1 drug
AADI SUB 1 drug
GLAND 1 drug
By Therapeutic Area
Other 5 drugs
SIROLIMUS, RAPAMUNE, HYFTOR, FYARRO +1 more
Oncology 4 drugs
AFINITOR, AFINITOR DISPERZ, TEMSIROLIMUS, TORISEL
Indications Treated
Malignant Perivascular Epithelioid Cell TumorOrgan RejectionLymphangioleiomyomatosisRenal Cell CarcinomaBreast CancerNeuroendocrine TumorsRenal AngiomyolipomaTuberous Sclerosis ComplexSubependymal Giant Cell AstrocytomaSeizuresPartial-Onset SeizuresFacial AngiofibromaTuberous Sclerosis
All Drugs Targeting mTOR
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| AFINITOR Top | Novartis | 2009 | 7 | Oncology |
| AFINITOR DISPERZ Top | Novartis | 2012 | 7 | Oncology |
| SIROLIMUS | ALKEM LABS LTD | 2014 | 2 | |
| RAPAMUNE | PF PRISM CV | 1999 | 2 | |
| HYFTOR | NOBELPHARMA | 2022 | 2 | |
| FYARRO | AADI SUB | 2021 | 1 | |
| TEMSIROLIMUS | GLAND | 2018 | 1 | Oncology |
| ZORTRESS | Novartis | 2010 | 1 | |
| TORISEL | PF PRISM CV | 2007 | 1 | Oncology |